The observation that tumor inherent type I IFN signaling may be driving immune chemotherapeutic response and anti-tumor immunity led us to consider the potential reversibility of IRF9/IFN loss in human breast tumors, as a possible means for enhanced therapeutic response and prolonged survival. Here, IFNA1 is linked to breast neoplasm.